Table 1.
Search results: pooled analyses of patient-level data and meta-analyses of trial-level data from studies investigating DPP-4 inhibitors and GLP-1 receptor agonists
| First author, year of publication | References | Drug(s) assessed | Publication type | Met inclusion criteriaa |
|---|---|---|---|---|
| DPP-4 inhibitors | ||||
| Abbas, 2016 | [42] | Alogliptin, saxagliptin, and sitagliptin | Meta-analysis | Yes |
| Agarwal, 2014 | [33] | Allb | Meta-analysis | Yes |
| Cobble, 2012 | [66] | Saxagliptin | Narrative review | No |
| Engel, 2013 | [23] | Sitagliptin | Pooled analysis | Yes |
| Frederich, 2010 | [67] | Saxagliptin | Pooled analysis | No |
| Iqbal, 2014 | [24] | Saxagliptin | Pooled analysis | Yes |
| Johansen, 2012 | [68] | Linagliptin | Pooled analysis | No |
| Kongwatcharapong, 2016 | [38] | Allb | Meta-analysis | Yes |
| Kundu, 2016 | [39] | Alogliptin, sitagliptin, and saxagliptin | Meta-analysis | Yes |
| Lehrke, 2014 | [22] | Linagliptin | Pooled analysis | Yes |
| Li, 2016 | [40] | Allb | Meta-analysis | Yes |
| McInnes, 2015 | [25] | Vildagliptin | Pooled analysis | Yes |
| Monami, 2011 | [69] | Allb | Meta-analysis | No |
| Monami, 2012 | [10] | Allb | Meta-analysis | No |
| Monami, 2013 | [29] | Allb | Meta-analysis | Yes |
| Monami, 2014 | [34] | Allb | Meta-analysis | Yes |
| Patil, 2012 | [30] | Allb | Meta-analysis | Yes |
| Rosenstock, 2015 | [21] | Linagliptin | Pooled analysis | Yes |
| Savarese, 2015 | [36] | Allb | Meta-analysis | Yes |
| Schweizer, 2010 | [64] | Vildagliptin | Pooled analysis | No |
| Udell, 2015 | [37] | Alogliptin and saxagliptin | Meta-analysis | Yes |
| von Eynatten, 2013 | [70] | Linagliptin | Pooled analysis | No |
| Wang, 2016 | [41] | Allb | Meta-analysis | Yes |
| White, 2013 | [26] | Alogliptin | Pooled analysis | Yes |
| Williams-Herman, 2010 | [71] | Sitagliptin | Pooled analysis | No |
| Wu, 2013 | [31] | Allb | Meta-analysis | Yes |
| Wu, 2014 | [35] | Allb | Meta-analysis | Yes |
| Zhang, 2014 | [32] | Allb | Meta-analysis | Yesc |
| GLP-1 receptor agonists | ||||
| Ferdinand, 2016 | [54] | Dulaglutide | Pooled analysis | Yes |
| Fisher, 2015 | [53] | Albiglutide | Pooled analysis | Yes |
| Li, 2016 | [56] | Alld | Meta-analysis | Yes |
| Marso, 2011 | [50] | Liraglutide | Pooled analysis | Yes |
| Monami, 2009 | [72] | Alld | Meta-analysis | No |
| Monami, 2011 | [73] | Alld | Meta-analysis | No |
| Monami, 2013 | [12] | Alld | Meta-analysis | Yes |
| Ratner, 2011 | [51] | Exenatide | Pooled analysis | Yes |
| Seshasai, 2015 | [52] | Taspoglutide | Pooled analysis | Yes |
| Sun, 2012 | [55] | Alld | Pairwise and network meta-analysis | Yes |
| Wang, 2016 | [41] | Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide | Meta-analysis | Yes |
aPooled analyses and meta-analyses meeting inclusion criteria were those that reported CV events as a primary objective. All excluded papers were rejected on the basis that CV events were not explicitly reported (including papers containing no analysis of adverse events), or were rendered redundant because of updated analyses
bAlogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin ± dutogliptin
cDescribed CV events in general, which included MACE
dExenatide, liraglutide, albiglutide, taspoglutide, dulaglutide, lixisenatide ± semaglutide